Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMTX with free AI briefings, catalyst countdowns, and dilution alerts.

IMTX · Immatics N.V.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$276.6M Cash on Hand
15mo Cash Runway
Follow IMTX by email Get an email when IMTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMTX, unsubscribe in one click. Privacy

📣 What IMTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nab-paclitaxel Melanoma, Cutaneous Malignant Phase 3 · NCT06743126 Recruiting
Anzutresgene Autoleucel (IMA203) Melanoma, Cutaneous Malignant Phase 3 · NCT06743126 Recruiting
Renal Cell Carcinoma Peptides Vaccine IMA901 Metastatic Renal Cell Carcinoma Phase 3 · NCT01265901 Completed
Sunitinib Metastatic Renal Cell Carcinoma Phase 3 · NCT01265901 Completed
Therapeutic Liver Cancer Peptide Vaccine IMA970A Hepatocellular Carcinoma Phase 1/2 · NCT03203005 Completed
Monoclonal Antibody Refractory Cancer Phase 1/2 · NCT05958121 Recruiting
IMA402 and IMA401 Refractory Cancer Phase 1/2 · NCT05958121 Recruiting
Cytotoxic Chemotherapeutic Agent Refractory Cancer Phase 1/2 · NCT05958121 Recruiting
IMA402 and checkpoint inhibitor Refractory Cancer Phase 1/2 · NCT05958121 Recruiting
IMA402 Refractory Cancer Phase 1/2 · NCT05958121 Recruiting
IMA203CD8 Product Refractory Cancer Phase 1/2 · NCT03686124 Recruiting
IMA 950 CNS Tumor, Adult Phase 1/2 · NCT01920191 Completed
Arm B: Paclitaxel Merkel Cell Carcinoma Phase 2 · NCT02054884 Terminated
Colorectal Tumor-Associated Peptides Vaccine… Colorectal Carcinoma Phase 1/2 · NCT00785122 Completed
Synthetic Glioblastoma Tumor-associated… Glioblastoma Phase 1 · NCT02149225 Completed
IMA401 (Phase Ia) Refractory Cancer Phase 1 · NCT05359445 Active not recruiting

Also used in these trials (approved or third-party drugs, not IMTX's own candidates): Temozolomide, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Ipilimumab, Lifileucel, Nivolumab, Relatlimab, Paclitaxel, Dacarbazine, Cyclophosphamide, Pembrolizumab, Poly ICLC, Sargramostim.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMTX holds $276.6M in cash and short-term investments and burns about $55.5M/quarter from operations, an estimated runway of 15 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMTX files for a raise →

👥 Who Owns IMTX

Insiders 8.9% Institutions (100 holders) 67.4% Public and other holders 23.7%
HolderTypeShares% of sharesAs of
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 25,149,155 18.76% 2026-09-30
Vestal Point Capital, LP Institution (13G, 5%+) 15,515,304 11.57% 2026-09-30
RTW Investments, LP Institution (13G, 5%+) 12,869,340 9.60% 2026-03-31
PERCEPTIVE ADVISORS LLC
Director · +48,000 options
Insider 11,246,516 8.39% 2026-08-26
SUVRETTA CAPITAL MANAGEMENT, LLC Institution (13G, 5%+) 11,190,129 8.35% 2025-12-31
Montanova Capital, LLC Institution (13G, 5%+) 8,750,816 6.53% 2026-09-30
The Toronto-Dominion Bank Institution (13G, 5%+) 7,436,342 5.55% 2026-03-31
Mathias Hothum
Director · +48,000 options
Insider 329,521 0.25% 2026-03-17
Jasuja Harpreet Singh
Chief Executive Officer, Director
Insider 217,241 0.16% 2026-03-18
Peter Alan Chambre
Director · +48,000 options
Insider 105,987 0.08% 2026-03-18
Carsten Alexander Johannes Reinhardt
Chief Development Officer
Insider 47,781 0.04% 2026-03-18
Steffen Martin Walter
Chief Operating Officer
Insider 10,000 0.01% 2026-03-18

Share count 134,071,432 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.